DK215889D0 - Rekombinant antistof - Google Patents

Rekombinant antistof

Info

Publication number
DK215889D0
DK215889D0 DK215889A DK215889A DK215889D0 DK 215889 D0 DK215889 D0 DK 215889D0 DK 215889 A DK215889 A DK 215889A DK 215889 A DK215889 A DK 215889A DK 215889 D0 DK215889 D0 DK 215889D0
Authority
DK
Denmark
Prior art keywords
pct
sec
recombinant antibody
date
surface pocket
Prior art date
Application number
DK215889A
Other languages
English (en)
Other versions
DK215889A (da
Inventor
Mark William Bodmer
John Robert Adair
Nigel Richard Whittle
Alan Howard Lyons
Raymond John Owens
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd filed Critical Celltech Ltd
Publication of DK215889D0 publication Critical patent/DK215889D0/da
Publication of DK215889A publication Critical patent/DK215889A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK215889A 1987-09-04 1989-05-03 Rekombinant antistof DK215889A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878720833A GB8720833D0 (en) 1987-09-04 1987-09-04 Recombinant dna product
PCT/GB1988/000729 WO1989001782A1 (en) 1987-09-04 1988-09-05 Recombinant antibody

Publications (2)

Publication Number Publication Date
DK215889D0 true DK215889D0 (da) 1989-05-03
DK215889A DK215889A (da) 1989-05-03

Family

ID=10623277

Family Applications (3)

Application Number Title Priority Date Filing Date
DK216089A DK216089D0 (da) 1987-09-04 1989-05-03 Rekombinant antistof og fremgangsmaade til dets fremstilling
DK215889A DK215889A (da) 1987-09-04 1989-05-03 Rekombinant antistof
DK198902161A DK172630B1 (da) 1987-09-04 1989-05-03 Modificeret antistofmolekyle eller derivat heraf og fremgangsmåde til fremstilling af det modificerede antistofmolekyle

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK216089A DK216089D0 (da) 1987-09-04 1989-05-03 Rekombinant antistof og fremgangsmaade til dets fremstilling

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK198902161A DK172630B1 (da) 1987-09-04 1989-05-03 Modificeret antistofmolekyle eller derivat heraf og fremgangsmåde til fremstilling af det modificerede antistofmolekyle

Country Status (11)

Country Link
US (1) US5219996A (da)
EP (3) EP0348442B1 (da)
JP (3) JP2761012B2 (da)
AT (2) ATE102254T1 (da)
AU (3) AU617367B2 (da)
CA (2) CA1337641C (da)
DE (2) DE3888172T2 (da)
DK (3) DK216089D0 (da)
FI (3) FI892137A0 (da)
GB (1) GB8720833D0 (da)
WO (3) WO1989001974A1 (da)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625856B2 (en) * 1987-07-15 1992-07-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
KR0161525B1 (ko) * 1988-10-19 1998-12-01 리챠드 지. 워터맨 암치료를 위한 신규의 고친화성 변형된 항체군
US5215889A (en) * 1988-11-18 1993-06-01 The Regents Of The University Of California Catalytic and reactive polypeptides and methods for their preparation and use
US5162218A (en) * 1988-11-18 1992-11-10 The Regents Of The University Of California Conjugated polypeptides and methods for their preparation
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5714149A (en) * 1989-02-10 1998-02-03 Celltech Therapeutics Limited Crosslinked antibodies and processes for their preparation
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8903021D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
US5354554A (en) * 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8916400D0 (en) * 1989-07-18 1989-09-06 Dynal As Modified igg3
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5185433A (en) * 1990-04-09 1993-02-09 Centocor, Inc. Cross-linking protein compositions having two or more identical binding sites
US6495137B1 (en) 1990-04-19 2002-12-17 The Dow Chemical Company Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains
US5976531A (en) * 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
EP1291360A1 (en) * 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0618969B1 (en) * 1991-12-13 2003-06-25 The Dow Chemical Company Composite antibodies of human subgroup iv light chain capable of binding to tag-72
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US6365124B1 (en) * 1998-02-06 2002-04-02 Biocrystal, Ltd. Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
WO2001061351A1 (en) * 2000-02-17 2001-08-23 Laboratory Of Molecular Biophotonics Method for quantitatively detecting antigen
EP2341075A1 (en) 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
US20030158382A1 (en) 2000-04-21 2003-08-21 Nobutaka Wakamiya Novel collectins
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ATE320450T1 (de) * 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2490659C (en) 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
CA2525251C (en) * 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
KR20060041205A (ko) 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 양특이성 항체들의 다가 담체들
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20050079184A1 (en) * 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
US20070269428A1 (en) 2003-11-21 2007-11-22 Celltech R&D Limited Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (ko) * 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
WO2007031734A1 (en) * 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
EP2336181A1 (en) 2005-12-09 2011-06-22 UCB Pharma, S.A. Antibody molecules having specificity for human IL-6
CN101400703B (zh) 2006-02-01 2013-05-08 赛法隆澳大利亚控股有限公司 结构域抗体构建体
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
PT2125894T (pt) 2007-03-22 2019-02-27 Biogen Ma Inc Proteínas de ligação incluindo anticorpos, derivados de anticorpos e fragmentos de anticorpos que se ligam especificamente ao cd154 e as suas utilizações
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
AU2008261042A1 (en) * 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of CH1 domain
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
MX2010003718A (es) * 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
US9079947B2 (en) 2007-11-27 2015-07-14 The University Of British Columbia 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
EP2220117A2 (en) 2007-11-30 2010-08-25 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
JP2011509675A (ja) * 2008-01-18 2011-03-31 メディミューン，エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
JP2011515497A (ja) 2008-03-26 2011-05-19 セレラント セラピューティクス インコーポレイテッド 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
US8614295B2 (en) 2009-02-17 2013-12-24 Ucb Pharma S.A. Antibody molecules having specificity for human OX40
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
US8722860B2 (en) 2009-04-16 2014-05-13 Abbvie Biotherapeutics Inc. Anti-TNF-α antibodies and their uses
PE20120622A1 (es) 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
US20120283415A1 (en) 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
IN2012DN03348A (da) 2009-10-16 2015-10-23 Biorealites
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
TW201122101A (en) 2009-10-28 2011-07-01 Facet Biotech Corp Anti-EGFR antibodies and their uses
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
ES2594893T3 (es) 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anticuerpos anti HER2 y sus usos
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
SG10201510762YA (en) 2011-01-14 2016-01-28 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
SG10201701055WA (en) 2011-09-16 2017-03-30 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
CA2887880A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Proteomic identification of antibodies
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
KR102447350B1 (ko) 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
EP2970488A2 (en) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
MX2015012563A (es) 2013-03-15 2016-10-26 Abbvie Biotechnology Ltd Anticuerpos anti-cd25 y sus usos.
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
ES2916825T3 (es) 2014-01-20 2022-07-06 UCB Biopharma SRL Procedimiento para la reconstitución de una forma sólida de una composición farmacéutica
KR20230088389A (ko) 2014-02-11 2023-06-19 씨젠 인크. 단백질의 선택적 환원
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP2944962A1 (en) 2014-05-14 2015-11-18 UCB Biopharma SPRL Method for determining antibody specificity
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
BR112017013394B1 (pt) 2014-12-22 2024-02-06 Ucb Biopharma Sprl Método para fabricar proteína de interesse
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3288584A2 (en) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CA2987146A1 (en) 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
KR102770650B1 (ko) 2015-07-06 2025-02-19 유씨비 바이오파마 에스알엘 타우 결합 항체
WO2017027325A1 (en) * 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
US10906990B2 (en) 2015-08-19 2021-02-02 Riken Antibody with non-natural amino acid introduced therein
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
MY206805A (en) 2015-10-27 2025-01-08 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
GB201602414D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Biological materials and uses thereof
WO2017158084A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
JP6978427B2 (ja) 2016-03-17 2021-12-08 ヌマブ セラピューティクス アクチェンゲゼルシャフト 抗ＴＮＦα抗体とその機能性フラグメント
SMT202000706T1 (it) 2016-03-17 2021-01-05 Tillotts Pharma Ag Anticorpi anti-tnf alfa e frammenti funzionali di essi
EP3219727B1 (en) 2016-03-17 2020-12-16 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
CN108884156B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3504244A4 (en) 2016-08-26 2020-08-19 Agency for Science, Technology and Research MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
JP7337698B2 (ja) 2017-02-28 2023-09-04 シージェン インコーポレイテッド コンジュゲート化のためのシステイン突然変異抗体
US20200165347A1 (en) 2017-06-30 2020-05-28 Aslan Pharmaceuticals Pte Ltd Method of treatment using il-13r antibody
DK3720879T3 (da) 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
AU2019228339B2 (en) 2018-02-27 2025-02-27 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
PL3806898T3 (pl) 2018-06-18 2026-02-23 UCB Biopharma SRL Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
US20210277131A1 (en) 2019-03-26 2021-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF
US20220306736A1 (en) 2019-09-04 2022-09-29 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
US11802151B2 (en) 2019-11-04 2023-10-31 Code Biotherapeutics, Inc. Brain-specific angiogenesis inhibitor 1 (BAI1) antibodies and uses thereof
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
US20230416357A1 (en) 2020-12-07 2023-12-28 UCB Biopharma SRL Antibodies against interleukin-22
WO2022122654A1 (en) 2020-12-07 2022-06-16 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
US20240158503A1 (en) 2021-03-03 2024-05-16 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
TW202309088A (zh) 2021-04-30 2023-03-01 法商皮爾法伯製藥公司 新的穩定抗ｖｉｓｔａ抗體
EP4334355A1 (en) 2021-05-03 2024-03-13 UCB Biopharma SRL Antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
EP4482867A1 (en) 2022-02-23 2025-01-01 ASLAN Pharmaceuticals Pte Ltd Glycosylated form of anti-il13r antibody
EP4590335A1 (en) 2022-08-26 2025-07-30 ASLAN Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
EP4594352A1 (en) 2022-09-06 2025-08-06 ASLAN Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
AU2023408654A1 (en) 2022-12-22 2025-06-26 Julius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
EP4431526A1 (en) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof
TW202547865A (zh) 2024-05-17 2025-12-16 比利時商Ｕｃｂ生物製藥公司 具有il-11結合特異性的抗體
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS63501765A (ja) * 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
DE3888172T2 (de) 1994-06-30
JP2761012B2 (ja) 1998-06-04
DK216189A (da) 1989-05-03
EP0348442B1 (en) 1993-01-27
DE3888172D1 (de) 1994-04-07
FI892135A0 (fi) 1989-05-03
AU2301388A (en) 1989-03-31
ATE102254T1 (de) 1994-03-15
FI892136A7 (fi) 1989-05-03
DK216089A (da) 1989-05-03
AU2421888A (en) 1989-03-31
FI892137L (fi) 1989-05-03
AU614303B2 (en) 1991-08-29
EP0348442A1 (en) 1990-01-03
JPH02501191A (ja) 1990-04-26
FI892136A0 (fi) 1989-05-03
FI892137A7 (fi) 1989-05-03
AU611202B2 (en) 1991-06-06
US5219996A (en) 1993-06-15
FI892135A7 (fi) 1989-05-03
WO1989001782A1 (en) 1989-03-09
JPH02501800A (ja) 1990-06-21
DK172630B1 (da) 1999-03-22
EP0347433B1 (en) 1994-03-02
JPH02501190A (ja) 1990-04-26
WO1989001783A2 (en) 1989-03-09
FI892135L (fi) 1989-05-03
AU2301688A (en) 1989-03-31
WO1989001974A1 (en) 1989-03-09
ATE84973T1 (de) 1993-02-15
EP0329755A1 (en) 1989-08-30
DE3877955T2 (de) 1993-07-22
WO1989001783A3 (en) 1989-04-20
DK216089D0 (da) 1989-05-03
AU617367B2 (en) 1991-11-28
FI892137A0 (fi) 1989-05-03
DK216189D0 (da) 1989-05-03
CA1337641C (en) 1995-11-28
CA1337640C (en) 1995-11-28
DK215889A (da) 1989-05-03
DE3877955D1 (de) 1993-03-11
FI892136L (fi) 1989-05-03
JP2675380B2 (ja) 1997-11-12
GB8720833D0 (en) 1987-10-14
EP0347433A1 (en) 1989-12-27

Similar Documents

Publication Publication Date Title
DE3888172D1 (de) Rekombinant-antikörper.
ES2068907T3 (es) Secuencias de nucleotidos que codifican una proteina con actividad ureasica.
BR8806158A (pt) Processo para remocao de oxidos de enxofre de um gas,processo de conversao de hidrocarbonetos que emprega um material de alimentacao de hidrocarbonetos contendo enxofre;composicao de materia;e processo para producao de um componente metalico contendo oxigenio
FR2437213A1 (fr) Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
DE3163867D1 (en) Novel substituted pyrazinyl-1,2,4-oxadiazol-5-ones, a process for preparing same and a pharmaceutical composition containing same
PT96068A (pt) Processo para a producao de proteina biologicamente activa
DE3881217D1 (de) Extraktionsverfahren reiner fraktionen von laktoperoxidase und laktoferrin aus milchserum.
ES2058538T3 (es) Compuestos de proteina a purificados y procedimiento para su preparacion.
PT92148A (pt) Processo para a preparacao de pomada contendo colesterol para o tratamento topico de dermatoses
DE69006395D1 (de) Nährstoff-Zusammensetzungen für die Ergänzung an Aminosäuren bei Säugetieren.
NO895028L (no) Ny chimerisk transformerende vekstfaktor-beta.
PT81528B (pt) Processo para a sintese de peptideos
ATE108709T1 (de) Verfahren zum herstellen von klinkern.
GB8414354D0 (en) Purifying protein
DK0383599T3 (da) Protein-anticancermiddel
ATE113986T1 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
ES2173879T3 (es) Procedimiento para la preparacion de conjugados a base de un participe especifico en la fijacion y de una proteina que contiene hidratos de carbono
DK549886D0 (da) Enzymproces
ES2065525T3 (es) Mejoras relacionadas con el radiomarcado de las proteinas.
AU1062588A (en) Immunoassay utilizing microparticle neutralization
ES2049021T3 (es) Metodo de recuperar la proteina epi purificada a partir de una solucion, especialmente una solucion de fermentacion.
DE59611353D1 (de) Transketolase-verwandtes protein
HUT49151A (en) Process for production of biotinilated proteins
SE8701197D0 (sv) Selective decarborization of iron based material
BR8006731A (pt) Processo de metalizacao interna aplicado em ampola para garrafa termica

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment